Head-To-Head Analysis: Cabaletta Bio (NASDAQ:CABA) & ZyVersa Therapeutics (NASDAQ:ZVSA)

Cabaletta Bio (NASDAQ:CABA) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

3.9% of ZyVersa Therapeutics shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Cabaletta Bio has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Earnings & Valuation

This table compares Cabaletta Bio and ZyVersa Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86 million	($1.96)	-1.37
ZyVersa Therapeutics	N/A	N/A	-$9.41 million	($0.83)	-0.14

Cabaletta Bio is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cabaletta Bio and ZyVersa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cabaletta Bio and ZyVersa Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1	1	5	0	2.57
ZyVersa Therapeutics	0	0	0	0	0.00

Cabaletta Bio currently has a consensus target price of $15.50, indicating a potential upside of 476.21%. Given Cabaletta Bio’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Cabaletta Bio is more favorable than ZyVersa Therapeutics.

Summary

ZyVersa Therapeutics beats Cabaletta Bio on 6 of the 11 factors compared between the two stocks.

About Cabaletta Bio

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.